Research ExplorerPublicationsEndothelial progenitor cells and plasma vascular endothelial...

Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration

Standard

Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration. / Grierson, Rebecca; Stemplewitz, Birthe; Kunst, Frank; Berna, Marc J; Richard, Gisbert; Berna-Thill, Michelle.

In: J OCUL PHARMACOL TH, Vol. 29, No. 6, 2013, p. 530-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Grierson, R, Stemplewitz, B, Kunst, F, Berna, MJ, Richard, G & Berna-Thill, M 2013, 'Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration', J OCUL PHARMACOL TH, vol. 29, no. 6, pp. 530-8. https://doi.org/10.1089/jop.2012.0013

APA

Grierson, R., Stemplewitz, B., Kunst, F., Berna, M. J., Richard, G., & Berna-Thill, M. (2013). Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration. J OCUL PHARMACOL TH, 29(6), 530-8. https://doi.org/10.1089/jop.2012.0013

Vancouver

Grierson R, Stemplewitz B, Kunst F, Berna MJ, Richard G, Berna-Thill M. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration. J OCUL PHARMACOL TH. 2013;29(6):530-8. https://doi.org/10.1089/jop.2012.0013

Bibtex

@article{c9934e2de35c45c994e23f80793f161f,
title = "Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration",
abstract = "PURPOSE: To evaluate endothelial progenitor cell [late outgrowth endothelial progenitor cells (OECs)], vascular endothelial growth factor (VEGF), and stromal cell-derived factor 1α (SDF-1α) plasma levels as potential biomarkers before and during ranibizumab (Lucentis({\textregistered})) treatment for neovascular age-related macular degeneration (nvAMD).METHODS: Thirty-one patients with untreated nvAMD presenting for 3 consecutive intravitreal ranibizumab injections and a follow-up visit at 4 weeks intervals were enrolled. Peripheral blood was collected before each injection and at the follow-up visit and OEC clusters were cultured and evaluated according to previously published protocols. VEGF and SDF-1α plasma levels were measured by enzyme-linked immunosorbent assay and compared to values from healthy young and old control.RESULTS: Patients with a high OEC count before treatment presented significantly more often with a short symptom duration and a smaller choroidal neovascularization size. VEGF plasma levels were significantly higher in nvAMD (282.4±195.2 pg/mL) compared to young (45.5±6.8 pg/mL) and old control (46.1±8.5 pg/mL). OEC levels decreased nonsignificantly during ranibizumab treatment, returning to baseline levels after the third injection. VEGF and SDF-1α plasma levels decreased significantly during treatment toward control values. Patients needing retreatment after 3 ranibizumab injections had significantly higher VEGF plasma levels at pretreatment compared to patients not needing further treatment.CONCLUSIONS: The results presented here suggest that VEGF plasma levels may warrant further evaluation regarding biological, therapeutical, and predictive implications in nvAMD.",
keywords = "Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Biological Markers, Cell Count, Chemokine CXCL12, Choroidal Neovascularization, Drug Administration Schedule, Endothelial Cells, Endothelium, Vascular, Female, Humans, Intravitreal Injections, Macular Degeneration, Male, Treatment Outcome, Vascular Endothelial Growth Factor A",
author = "Rebecca Grierson and Birthe Stemplewitz and Frank Kunst and Berna, {Marc J} and Gisbert Richard and Michelle Berna-Thill",
year = "2013",
doi = "10.1089/jop.2012.0013",
language = "English",
volume = "29",
pages = "530--8",
journal = "J OCUL PHARMACOL TH",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration

AU - Grierson, Rebecca

AU - Stemplewitz, Birthe

AU - Kunst, Frank

AU - Berna, Marc J

AU - Richard, Gisbert

AU - Berna-Thill, Michelle

PY - 2013

Y1 - 2013

N2 - PURPOSE: To evaluate endothelial progenitor cell [late outgrowth endothelial progenitor cells (OECs)], vascular endothelial growth factor (VEGF), and stromal cell-derived factor 1α (SDF-1α) plasma levels as potential biomarkers before and during ranibizumab (Lucentis(®)) treatment for neovascular age-related macular degeneration (nvAMD).METHODS: Thirty-one patients with untreated nvAMD presenting for 3 consecutive intravitreal ranibizumab injections and a follow-up visit at 4 weeks intervals were enrolled. Peripheral blood was collected before each injection and at the follow-up visit and OEC clusters were cultured and evaluated according to previously published protocols. VEGF and SDF-1α plasma levels were measured by enzyme-linked immunosorbent assay and compared to values from healthy young and old control.RESULTS: Patients with a high OEC count before treatment presented significantly more often with a short symptom duration and a smaller choroidal neovascularization size. VEGF plasma levels were significantly higher in nvAMD (282.4±195.2 pg/mL) compared to young (45.5±6.8 pg/mL) and old control (46.1±8.5 pg/mL). OEC levels decreased nonsignificantly during ranibizumab treatment, returning to baseline levels after the third injection. VEGF and SDF-1α plasma levels decreased significantly during treatment toward control values. Patients needing retreatment after 3 ranibizumab injections had significantly higher VEGF plasma levels at pretreatment compared to patients not needing further treatment.CONCLUSIONS: The results presented here suggest that VEGF plasma levels may warrant further evaluation regarding biological, therapeutical, and predictive implications in nvAMD.

AB - PURPOSE: To evaluate endothelial progenitor cell [late outgrowth endothelial progenitor cells (OECs)], vascular endothelial growth factor (VEGF), and stromal cell-derived factor 1α (SDF-1α) plasma levels as potential biomarkers before and during ranibizumab (Lucentis(®)) treatment for neovascular age-related macular degeneration (nvAMD).METHODS: Thirty-one patients with untreated nvAMD presenting for 3 consecutive intravitreal ranibizumab injections and a follow-up visit at 4 weeks intervals were enrolled. Peripheral blood was collected before each injection and at the follow-up visit and OEC clusters were cultured and evaluated according to previously published protocols. VEGF and SDF-1α plasma levels were measured by enzyme-linked immunosorbent assay and compared to values from healthy young and old control.RESULTS: Patients with a high OEC count before treatment presented significantly more often with a short symptom duration and a smaller choroidal neovascularization size. VEGF plasma levels were significantly higher in nvAMD (282.4±195.2 pg/mL) compared to young (45.5±6.8 pg/mL) and old control (46.1±8.5 pg/mL). OEC levels decreased nonsignificantly during ranibizumab treatment, returning to baseline levels after the third injection. VEGF and SDF-1α plasma levels decreased significantly during treatment toward control values. Patients needing retreatment after 3 ranibizumab injections had significantly higher VEGF plasma levels at pretreatment compared to patients not needing further treatment.CONCLUSIONS: The results presented here suggest that VEGF plasma levels may warrant further evaluation regarding biological, therapeutical, and predictive implications in nvAMD.

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors

KW - Antibodies, Monoclonal, Humanized

KW - Biological Markers

KW - Cell Count

KW - Chemokine CXCL12

KW - Choroidal Neovascularization

KW - Drug Administration Schedule

KW - Endothelial Cells

KW - Endothelium, Vascular

KW - Female

KW - Humans

KW - Intravitreal Injections

KW - Macular Degeneration

KW - Male

KW - Treatment Outcome

KW - Vascular Endothelial Growth Factor A

U2 - 10.1089/jop.2012.0013

DO - 10.1089/jop.2012.0013

M3 - SCORING: Journal article

C2 - 23573802

VL - 29

SP - 530

EP - 538

JO - J OCUL PHARMACOL TH

JF - J OCUL PHARMACOL TH

SN - 1080-7683

IS - 6

ER -